|
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced
that Dr. Mario Cardiel, one of its principal investigators, reviewed
previously released data from its Phase 3 clinical trial of Riquent(TM)
for the treatment of lupus renal disease at the Annual European
Congress of Rheumatology "EULAR 2003" in Lisbon, Portugal. His presentation
entitled "Randomized, Placebo-controlled, Double-blind, Phase 3
Clinical Trial for the Evaluation of Riquent (LJP 394) in the Treatment
of Patients with SLE Who Are at Risk for Renal Flare" was given
today.
La Jolla Pharmaceutical Company is a biotechnology
company developing therapeutics for antibody-mediated autoimmune
diseases afflicting several million people in the United States
and Europe. The Company is developing Riquent(TM), formerly known
as LJP 394, for the treatment of lupus kidney disease, a leading
cause of sickness and death in patients with lupus. The Company
is also developing LJP 1082 for the treatment of antibody-mediated
thrombosis, a condition in which patients suffer from recurrent
stroke, deep- vein thrombosis and other thrombotic events. The Company's
common stock is traded on The Nasdaq Stock Market under the symbol
LJPC. For more information about the Company, visit its Web site:
http://www.ljpc.com/.
|
Message
Boards
